Fig. 1
DS-1001b impairs the proliferation of IDH1 mutant chondrosarcoma cell lines and decreases 2-HG levels. a Chemical structure of DS-1001b. b Comparison of intracellular 2-HG levels in chondrosarcoma cell lines treated with 1 and 10 μM DS-1001b for 72 h. The chondrosarcoma cell lines OUMS27 (IDH WT), NDCS-1 (IDH WT), JJ012 (IDH1R132G), L835 (IDH1R132C), and SW1353 (IDH2R172S) were used. N.D., not detected. c Bar graphs show intracellular D-2-HG and L-2-HG levels in JJ012 and L835 cells treated with 1 μM DS-1001b for 72 h. N.D., not detected. d Cell proliferation of JJ012 and L835 cells treated with different concentrations of DS-1001b for the indicated times. The Y-axis shows the cumulative cell numbers. e Cell viability of JJ012 and L835 cells treated with different concentrations of DS-1001b. JJ012 cells were treated with DS-1001b for 7 days under normoxic (monolayer) and hypoxic (1% O2) conditions, and in 3D cultures (spheroids). L835 cells were treated for 3 weeks under normoxic (monolayer) and hypoxic conditions (1% O2). f Relative 2-HG levels in JJ012 and L835 cells treated with different concentrations of DS-1001b for 72 h. The levels were normalized to vehicle treatment. All data represent the mean of triplicates ± s.d. *P < 0.001, **P < 0.05 (Student’s t-test)
